Watch Demo

In Vivo CRO Market Research Report by Type, GLP Type, Indication, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

In Vivo CRO Market Research Report by Type, GLP Type, Indication, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:133

  • Report ID:6398082

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

In Vivo CRO Market Research Report by Type (Non-Rodent and Rodent), GLP Type, Indication, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

The United States In Vivo CRO Market size was estimated at USD 853.49 million in 2022 and expected to reach USD 920.75 million in 2023, projecting growth at a CAGR of 9.34% to reach USD 1,744.52 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States In Vivo CRO Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States In Vivo CRO Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States In Vivo CRO Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States In Vivo CRO Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States In Vivo CRO Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market is studied across Non-Rodent and Rodent. The Rodent is further studied across Mice and Rats.

Based on GLP Type, the market is studied across GLP Toxicology and Non-GLP. The GLP Toxicology is further studied across In House and Outsourcing. The Non-GLP is further studied across In House and Outsourcing.

Based on Indication, the market is studied across Autoimmune/inflammation conditions, Blood Cancer, CNS conditions, Diabetes, Obesity, Oncology, Pain management, and Solid Tumor. The Autoimmune/inflammation conditions is further studied across Irritable Bowel Syndrome, Multiple Sclerosis, Osteoarthritis, and Rheumatoid Arthritis. The CNS conditions is further studied across ALS, Epilepsy, Huntington’s Disease, Muscle Regeneration, Parkinson’s Disease, Stroke, and Traumatic Brain Injury. The Pain management is further studied across Acute Pain and Chronic Pain. The Solid Tumor is further studied across Patient-derived Xenograft, Syngeneic Model, and Xenograft.

Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States In Vivo CRO Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States In Vivo CRO Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States In Vivo CRO Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States In Vivo CRO Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States In Vivo CRO Market, including Charles River Laboratories, Crown Bioscience, Inc., Eurofins Scientific SE, Evotec SE, ICON Plc, Labcorp Drug Development, Medpace, Inc., MI Bioresearch, Inc., Parexel International Corporation, Pharmacology Discovery Services, PPD Inc., Syneos Health, Syngene International Limited, Taconic Biosciences, Inc., and WuXi AppTec, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States In Vivo CRO Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States In Vivo CRO Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States In Vivo CRO Market?
4. What is the competitive strategic window for opportunities in the United States In Vivo CRO Market?
5. What are the technology trends and regulatory frameworks in the United States In Vivo CRO Market?
6. What is the market share of the leading vendors in the United States In Vivo CRO Market?
7. What modes and strategic moves are considered suitable for entering the United States In Vivo CRO Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing usage of In vivo CRO services due to their multifaceted benefits
5.1.1.2. Growing focus on the development of biosimilar medicines and drugs
5.1.2. Restraints
5.1.2.1. High cost of clinical trials
5.1.3. Opportunities
5.1.3.1. Increasing utilization of advanced technologies by In vivo CROs
5.1.4. Challenges
5.1.4.1. Quality and contamination issues
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. In Vivo CRO Market, by Type
6.1. Introduction
6.2. Non-Rodent
6.3. Rodent
6.4.1. Mice
6.4.2. Rats

7. In Vivo CRO Market, by GLP Type
7.1. Introduction
7.2. GLP Toxicology
7.3.1. In House
7.3.2. Outsourcing
7.3. Non-GLP
7.4.1. In House
7.4.2. Outsourcing

8. In Vivo CRO Market, by Indication
8.1. Introduction
8.2. Autoimmune/inflammation conditions
8.3.1. Irritable Bowel Syndrome
8.3.2. Multiple Sclerosis
8.3.3. Osteoarthritis
8.3.4. Rheumatoid Arthritis
8.3. Blood Cancer
8.4. CNS conditions
8.5.1. ALS
8.5.2. Epilepsy
8.5.3. Huntington's Disease
8.5.4. Muscle Regeneration
8.5.5. Parkinson's Disease
8.5.6. Stroke
8.5.7. Traumatic Brain Injury
8.5. Diabetes
8.6. Obesity
8.7. Oncology
8.8. Pain management
8.9.1. Acute Pain
8.9.2. Chronic Pain
8.9. Solid Tumor
8.10.1. Patient-derived Xenograft
8.10.2. Syngeneic Model
8.10.3. Xenograft

9. California In Vivo CRO Market
9.1. Introduction

10. Florida In Vivo CRO Market
10.1. Introduction

11. Illinois In Vivo CRO Market
11.1. Introduction

12. New York In Vivo CRO Market
12.1. Introduction

13. Ohio In Vivo CRO Market
13.1. Introduction

14. Pennsylvania In Vivo CRO Market
14.1. Introduction

15. Texas In Vivo CRO Market
15.1. Introduction

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Product Portfolio Analysis, By Key Player
16.5. Competitive Scenario
16.5.1. Merger & Acquisition
16.5.2. Agreement, Collaboration, & Partnership
16.5.3. New Product Launch & Enhancement
16.5.4. Investment & Funding
16.5.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. Charles River Laboratories
17.2. Crown Bioscience, Inc.
17.3. Eurofins Scientific SE
17.4. Evotec SE
17.5. ICON Plc
17.6. Labcorp Drug Development
17.7. Medpace, Inc.
17.8. MI Bioresearch, Inc.
17.9. Parexel International Corporation
17.10. Pharmacology Discovery Services
17.11. PPD Inc.
17.12. Syneos Health
17.13. Syngene International Limited
17.14. Taconic Biosciences, Inc.
17.15. WuXi AppTec, Inc.

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES IN VIVO CRO MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES IN VIVO CRO MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES IN VIVO CRO MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES IN VIVO CRO MARKET DYNAMICS
FIGURE 8. UNITED STATES IN VIVO CRO MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES IN VIVO CRO MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2030
FIGURE 12. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-RODENT, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES IN VIVO CRO MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES IN VIVO CRO MARKET SIZE, BY RATS, 2018-2030 (USD MILLION)
FIGURE 16. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2022 VS 2030 (%)
FIGURE 17. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES IN VIVO CRO MARKET COMPETITIVE STRATEGIC WINDOW, BY GLP TYPE, 2030
FIGURE 19. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
FIGURE 20. UNITED STATES IN VIVO CRO MARKET SIZE, BY IN HOUSE, 2018-2030 (USD MILLION)
FIGURE 21. UNITED STATES IN VIVO CRO MARKET SIZE, BY OUTSOURCING, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
FIGURE 23. UNITED STATES IN VIVO CRO MARKET SIZE, BY IN HOUSE, 2018-2030 (USD MILLION)
FIGURE 24. UNITED STATES IN VIVO CRO MARKET SIZE, BY OUTSOURCING, 2018-2030 (USD MILLION)
FIGURE 25. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 26. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES IN VIVO CRO MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 28. UNITED STATES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
FIGURE 29. UNITED STATES IN VIVO CRO MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2030 (USD MILLION)
FIGURE 30. UNITED STATES IN VIVO CRO MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
FIGURE 31. UNITED STATES IN VIVO CRO MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
FIGURE 32. UNITED STATES IN VIVO CRO MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
FIGURE 33. UNITED STATES IN VIVO CRO MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
FIGURE 34. UNITED STATES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
FIGURE 35. UNITED STATES IN VIVO CRO MARKET SIZE, BY ALS, 2018-2030 (USD MILLION)
FIGURE 36. UNITED STATES IN VIVO CRO MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
FIGURE 37. UNITED STATES IN VIVO CRO MARKET SIZE, BY HUNTINGTON'S DISEASE, 2018-2030 (USD MILLION)
FIGURE 38. UNITED STATES IN VIVO CRO MARKET SIZE, BY MUSCLE REGENERATION, 2018-2030 (USD MILLION)
FIGURE 39. UNITED STATES IN VIVO CRO MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
FIGURE 40. UNITED STATES IN VIVO CRO MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
FIGURE 41. UNITED STATES IN VIVO CRO MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2030 (USD MILLION)
FIGURE 42. UNITED STATES IN VIVO CRO MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
FIGURE 43. UNITED STATES IN VIVO CRO MARKET SIZE, BY OBESITY, 2018-2030 (USD MILLION)
FIGURE 44. UNITED STATES IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
FIGURE 45. UNITED STATES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
FIGURE 46. UNITED STATES IN VIVO CRO MARKET SIZE, BY ACUTE PAIN, 2018-2030 (USD MILLION)
FIGURE 47. UNITED STATES IN VIVO CRO MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
FIGURE 48. UNITED STATES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
FIGURE 49. UNITED STATES IN VIVO CRO MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT, 2018-2030 (USD MILLION)
FIGURE 50. UNITED STATES IN VIVO CRO MARKET SIZE, BY SYNGENEIC MODEL, 2018-2030 (USD MILLION)
FIGURE 51. UNITED STATES IN VIVO CRO MARKET SIZE, BY XENOGRAFT, 2018-2030 (USD MILLION)
FIGURE 52. CALIFORNIA IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. FLORIDA IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. ILLINOIS IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. NEW YORK IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. OHIO IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. PENNSYLVANIA IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. TEXAS IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. UNITED STATES IN VIVO CRO MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 60. UNITED STATES IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 61. UNITED STATES IN VIVO CRO MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. UNITED STATES IN VIVO CRO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-RODENT, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES IN VIVO CRO MARKET SIZE, BY RODENT, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES IN VIVO CRO MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES IN VIVO CRO MARKET SIZE, BY MICE, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES IN VIVO CRO MARKET SIZE, BY RATS, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES IN VIVO CRO MARKET SIZE, BY RATS, BY STATE, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, BY STATE, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES IN VIVO CRO MARKET SIZE, BY IN HOUSE, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY STATE, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES IN VIVO CRO MARKET SIZE, BY OUTSOURCING, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-GLP, BY STATE, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES IN VIVO CRO MARKET SIZE, BY IN HOUSE, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY STATE, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES IN VIVO CRO MARKET SIZE, BY OUTSOURCING, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES IN VIVO CRO MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES IN VIVO CRO MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES IN VIVO CRO MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES IN VIVO CRO MARKET SIZE, BY MULTIPLE SCLEROSIS, BY STATE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES IN VIVO CRO MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES IN VIVO CRO MARKET SIZE, BY OSTEOARTHRITIS, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES IN VIVO CRO MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES IN VIVO CRO MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES IN VIVO CRO MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES IN VIVO CRO MARKET SIZE, BY BLOOD CANCER, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, BY STATE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES IN VIVO CRO MARKET SIZE, BY ALS, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES IN VIVO CRO MARKET SIZE, BY ALS, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES IN VIVO CRO MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES IN VIVO CRO MARKET SIZE, BY EPILEPSY, BY STATE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES IN VIVO CRO MARKET SIZE, BY HUNTINGTON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES IN VIVO CRO MARKET SIZE, BY HUNTINGTON'S DISEASE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES IN VIVO CRO MARKET SIZE, BY MUSCLE REGENERATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES IN VIVO CRO MARKET SIZE, BY MUSCLE REGENERATION, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES IN VIVO CRO MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES IN VIVO CRO MARKET SIZE, BY PARKINSON'S DISEASE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES IN VIVO CRO MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES IN VIVO CRO MARKET SIZE, BY STROKE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES IN VIVO CRO MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES IN VIVO CRO MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IN VIVO CRO MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES IN VIVO CRO MARKET SIZE, BY DIABETES, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IN VIVO CRO MARKET SIZE, BY OBESITY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES IN VIVO CRO MARKET SIZE, BY OBESITY, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES IN VIVO CRO MARKET SIZE, BY ACUTE PAIN, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES IN VIVO CRO MARKET SIZE, BY ACUTE PAIN, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES IN VIVO CRO MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES IN VIVO CRO MARKET SIZE, BY CHRONIC PAIN, BY STATE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES IN VIVO CRO MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES IN VIVO CRO MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES IN VIVO CRO MARKET SIZE, BY SYNGENEIC MODEL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES IN VIVO CRO MARKET SIZE, BY SYNGENEIC MODEL, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES IN VIVO CRO MARKET SIZE, BY XENOGRAFT, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES IN VIVO CRO MARKET SIZE, BY XENOGRAFT, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. CALIFORNIA IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 77. CALIFORNIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. CALIFORNIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
TABLE 79. CALIFORNIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. FLORIDA IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 81. FLORIDA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. FLORIDA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
TABLE 83. FLORIDA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. ILLINOIS IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 85. ILLINOIS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. ILLINOIS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
TABLE 87. ILLINOIS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. NEW YORK IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 89. NEW YORK IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. NEW YORK IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
TABLE 91. NEW YORK IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. OHIO IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 93. OHIO IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. OHIO IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
TABLE 95. OHIO IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. PENNSYLVANIA IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 97. PENNSYLVANIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. PENNSYLVANIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
TABLE 99. PENNSYLVANIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. TEXAS IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 101. TEXAS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. TEXAS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
TABLE 103. TEXAS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES IN VIVO CRO MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 105. UNITED STATES IN VIVO CRO MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 106. UNITED STATES IN VIVO CRO MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 107. UNITED STATES IN VIVO CRO MARKET RANKING, BY KEY PLAYER, 2022
TABLE 108. UNITED STATES IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2022
TABLE 109. UNITED STATES IN VIVO CRO MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 110. UNITED STATES IN VIVO CRO MARKET MERGER & ACQUISITION
TABLE 111. UNITED STATES IN VIVO CRO MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 112. UNITED STATES IN VIVO CRO MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 113. UNITED STATES IN VIVO CRO MARKET INVESTMENT & FUNDING
TABLE 114. UNITED STATES IN VIVO CRO MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 115. UNITED STATES IN VIVO CRO MARKET: LICENSE & PRICING

Companies Mentioned

Charles River Laboratories
Crown Bioscience, Inc.
Eurofins Scientific SE
Evotec SE
ICON Plc
Labcorp Drug Development
Medpace, Inc.
MI Bioresearch, Inc.
Parexel International Corporation
Pharmacology Discovery Services
PPD Inc.
Syneos Health
Syngene International Limited
Taconic Biosciences, Inc.
WuXi AppTec, Inc.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.